

Market Announcement

4 June 2024

LTR Pharma Limited (ASX: LTP) – Trading Halt

Description

The securities of LTR Pharma Limited ('LTP') will be placed in trading halt at the request of LTP, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 6 June 2024 or when the announcement is released to the market.

Issued by

ASX Compliance



4 June 2024

Melissa Kostopoulos
ASX Compliance Pty Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

By email: tradinghaltsmelbourne@asx.com.au

Dear Melissa

TRADING HALT REQUEST – ASX CODE: LTP

LTR Pharma Limited (ASX:LTP) (“LTR Pharma”, “the Company”), requests a trading halt in respect of its securities pursuant to Listing Rule 17.1 with immediate effect.

In accordance with ASX Listing Rule 17.1, LTR Pharma advises that:

1. The trading halt is necessary pending an analysis of data and an announcement by the Company in relation to the initial clinical trial results of its pivotal study of SPONTAN® Nasal Spray treatment of Erectile Dysfunction;
2. LTR Pharma requests that the trading halt remain in place until the Company releases an announcement in relation to the clinical trial results or until the commencement of trading on Thursday 6 June 2024, whichever is earlier;
3. LTR Pharma confirms that it is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market regarding the trading halt.

Kind regards

Belinda Cleminson
Company Secretary

About LTR Pharma

LTR Pharma is focused on improving men's health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma's lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.